Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 4/20 | 0.44 |
| ▸ | ABL1 | P00519 | 2/20 | 0.41 |
| ▸ | MAP4K1 | Q92918 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | S100A4 | P26447 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | WNT1 | P04628 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3434576 | 0.85 | MAPK1 (0.45) | NPC1RAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL3434314 | 0.85 | TRPV1 (0.40) | ABL1MAP4K1KDM4EMAPK1WNT1 | |
| SCHEMBL1505531 | 0.83 | GCK (0.43) | GCK | |
| SCHEMBL3431725 | 0.83 | MAPK1 (0.38) | ABL1MAPK1 | |
| SCHEMBL3433064 | 0.83 | MAPK1 (0.38) | MAPK1 | |
| SCHEMBL3433278 | 0.82 | MAP4K1 (0.43) | MAP4K1KDM4ENPC1RAB9AHTT | |
| SCHEMBL3434320 | 0.82 | NPC1 (0.47) | MAP4K1NPC1MAPK1 | |
| SCHEMBL3434663 | 0.81 | RAB9A (0.38) | GCKKDM4ENPC1RAB9AHTT | |
| SCHEMBL3433076 | 0.75 | CYP2A6 (0.48) | GCKABL1 | |
| SCHEMBL3432655 | 0.75 | PDE10A (0.41) | KDM4ENPC1RAB9ASMN1; SMN2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101100-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF-211 | ASTRAZENECA AB (SE) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101100-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF-211 | UROD, UMPS, SLC14A1 | GCK 1931/4885ABL1 1017/4885MAP4K1 2858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.